Influenza Diagnostics Market Share

Influenza Diagnostics Market Overview

Market Research Future (MRFR) studied the Influenza Diagnostics Market is expected to reach USD 1.81 Billion by 2032 at CAGR 5.3% during the forecast period 2023-2032.

A contagious respiratory infection induced by several flu viruses is called influenza. Every year, a large number of people is afflicted with seasonal influenza that result in hospitalizations and flu-related deaths of a large number of people, especially the aging patient population.

COVID-19 Analysis

The impact evaluation of the influenza diagnosis market for COVID-19 is recorded in the report. The report details the impact of new policies by governments on the healthcare field due to the pandemic. The outbreak of COVID 19 has detrimental effect on the world health and medical system. The report describes solutions that are deployed to counter the decline in healthcare system of the world. Other major issues are elaborated in detail in the report.

Influenza Diagnostics Market Trends

The growing prevalence of influenza creating the need to deliver effective treatment can favor the expansion of the influenza diagnostic market. In addition, a rise in funding for research in influenza diagnosis can add to the market expansion. The fast-growing demand for quick diagnostic solutions can favor market expansion in the years to come. The increase in awareness about such disease and the introduction of quadrivalent influenza vaccines can drive the influenza diagnostics market in the coming years.

The emergence of startups exploring the untapped potential of the market can contribute to the creating of numerous revenue generation pockets for the market by 2023. The introduction of disruptive technologies, such as artificial intelligence, favoring innovations in diagnostic solutions can support the market rise.

The gradual rise in healthcare expenses and issues with inaccuracy in diagnostic solutions can hinder the influenza diagnostics market rise in the years to come.

Influenza Diagnostics Market Segment Insights

Influenza Diagnostics Type of Flu Insights

The type A flu segment can rise at a substantial pace with decent CAGR. The segment can acquire a USD 954.512 Million influenza diagnostics market share by 2023. The type B flu segment can rise at 8.66% CAGR from 2018 to 2023. The increase in initiatives by the government to curb influenza is likely to boost market growth.

Influenza Diagnostics Test Type Insights

The molecular diagnostic tests segment can exhibit the highest CAGR along the evaluation tenure as physicians are inclined towards accurate diagnostic solutions. The traditional diagnostics segment can also thrive in the approaching years.

Influenza Diagnostics End-User Insights

The point of care testing segment can retain the leading position in the global influenza diagnostics market by 2023. The segment can exhibit decent CAGR through the analysis tenure. An increase in number of clinicals dedicated to diagnosis and treatment of influenza can drive the hospital and clinical laboratories segment growth.

Influenza Diagnostics Regional Insights

In Americas, the influenza diagnostics market can secure 38.0% share of the global market value by 2023. The regional influenza diagnostics market can thrive across the forecast tenure due to increase in prevalence of influenza and the ease of availability of advanced healthcare facilities.

In Europe, the aviation test equipment market can secure the second-largest share of the global market. The rise in count of pharmaceutical companies dealing in exporting their products is also responsible for growth of the regional market. Rise in disease awareness, and extended recommendations by advisory bodies and governmental for vaccination against influenza can contribute to the market upsurge.

Asia Pacific influenza diagnostics market can secure the forefront position in the global lead. This can be attributed to rapid development in healthcare infrastructure and growing prevalence of endocrinology, lymphatic systems, cardiovascular, and respiratory disorders.

Competitive Landscape

MRFR enlisted renowned companies that are operating in the global influenza diagnostics market. The competitive analysis of the influenza diagnostics market consists of market share analysis, financial analysis, and product benchmarking. Alongside, strategic developments in the market that include mergers & acquisitions, product launches, and joint ventures are also studied by MRFR analysts that can help in understanding regional progress and growth scopes offered by these enterprises.

List of Key Companies Covered in this Report

• Coris BioConcept


• DiaSorin S.p.A


• Alere Inc.


• Lonza


• Ortho-Clinical Diagnostics


• Qiagen


• Wako


• Abbott


• Analytik Jena AG


• Becton, Dickinson and Company,


• Biocartis,


• bioMérieux Inc,


• Cepheid,


• DiaSorin S.p.A., F.


• Hoffmann-La Roche Ltd,


• GenMark Diagnostics, Inc.,


• Luminex Corporation,


• Meridian Bioscience, Inc.,


• Quidel Corporation,


• SA Scientific,


• Thermo Fisher Scientific Inc.

Recent Developments

• 
  February 2023- The Molecular Diagnostic System is a powerful tool for quickly identifying and distinguishing between COVID-19, the flu, and RSV. By taking a single nasal swab or a single nasopharyngeal swab sample, it can analyze the sample and provide results in as little as two hours. This makes it incredibly useful for quickly diagnosing and treating patients with the most appropriate care. Furthermore, the system is highly accurate, meaning that patients can be confident that they are receiving the right diagnosis and treatment. The Molecular Diagnostic System is an invaluable tool in the fight against the spread of infectious diseases like COVID-19, the flu, and RSV.


• 
  January 2021-Labs that are performing Flu SC2 Multiplex Assay recognized by the Centers for Disease Control’s (CDC), which is a single test to diagnose infection caused due to influenza A, SARS-CoV-2, or influenza B, can now use a Promega nucleic acid purification kit and two Promega instruments. Promega is a Wisconsin-based producer of enzymes and other types of molecular biology and biotechnology portfolio


• 
  January 2021-GeneIQ, a Texas-based molecular diagnostics laboratory that offer COVID-19 testing across the country, announced the introduction of combined PCR test for influenza A (Flu A), viruses SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV), and influenza B (Flu B).

Influenza Diagnostics Market Segmentation

Market analysis, sizing, and forecast of the influenza diagnostics market are covered in the report. The country-level assessment of the market and associated forecasts are explained in the influenza diagnostics market report. The expansion of the influenza diagnostic controlling market dynamics intelligence that includes, market drivers, opportunities, supply chain, restraints, trends, value chain analysis, and Porter’s five forces are studied by MRFR analysts. Patent analysis outlook, Technology trends, and regulatory landscape of the market is detailed in the report to help investors acquire an in-depth understanding of the market and associated activities.

Influenza Diagnostics Type of Flu Outlook

• Type A Flu


• Type B Flu


• Type C Flu

Influenza Diagnostics Test Type Outlook

• Traditional Diagnostic Tests


• 
  Molecular Diagnostic Tests

Influenza Diagnostics End-User Outlook

• Hospitals & Clinical Laboratories


• Point-of-Care Testing